Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study

Although immune checkpoint inhibitor therapy has led to modest response rates in patients with advanced urothelial cancer, the combination of chemotherapy with immune checkpoint inhibition has not been previously clinically studied. In this phase I study, we found that the combination of pembrolizum...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Genitourin Cancer
Hauptverfasser: Parikh, Mamta, Pan, Chong-Xian, Beckett, Laurel A., Li, Yueju, Robles, Daniel A., Aujla, Pawandeep K., Lara, Primo N.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6450697/
https://ncbi.nlm.nih.gov/pubmed/30166228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.07.004
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge